zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma
Published 2 years ago • 86 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
3:16
zuma-12: a phase 2 study of axi-cel as first-line therapy in patients with high-risk large b-cel...
-
3:55
zuma-12: axicabtagene ciloleucel for high-risk large b cell lymphoma
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
3:10
zuma-9: expanded access protocol and oos axicabtagene ciloleucel in r/r dlbcl
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:08
zuma-7: overall survival benefit of axi-cel over soc in second-line lbcl
-
1:20
axi-cel in r/r fl: an updated comparison of zuma-5 and the scholar-5 external control cohort
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
-
3:31
zuma-1 trial observations
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
2:43
long-term follow-up results of zuma-5: axi-cel in patients with r/r indolent nhl
-
1:11
zuma-11 study overview: axi-cel plus utomilumab in r/r dlbcl
-
2:09
zuma series update: zuma-1 and zuma-2
-
4:03
axi-cel plus rituximab for r/r lbcl and updates from the zuma-14 study
-
1:44
comparison of zuma-1 and scholar-1 outcomes